ASH 2015 - Multiple Myeloma
Researchers presented data relating to the management of infusion-related reactions (IRRs) associated with single-agent daratumumab treatment in patients with relapsed or refractory multiple myeloma (RRMM) enrolled in the open-label, multicenter, phase 2 Sirius study.
Researchers present the final data for the secondary end point of overall survival across the entire study population of the phase 3 clinical trial PANORAMA 1, which evaluated panobinostat in combination with bortezomib and dexamethasone. Overall survival was not statistically significant.
Bortezomib/Melphalan/Prednisolone Induction Therapy Followed by Lenalidomide/Dexamethasone Consolidation and Lenalidomide Maintenance in Transplant-Ineligible Patients with Newly Diagnosed MM
The VISTA study demonstrated good tolerability of VMP; however, in a subsequent phase 2 trial, there was a higher rate of treatment discontinuation than expected. In this study, investigators demonstrated lowering the intensity of VMP proved to be both safe and effective for newly diagnosed multiple myeloma (NDMM).
Daratumumab plus Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a 4-Arm Phase 1b Study
Chari and colleagues presented results of a 4-arm phase 1b study that evaluated the safety and efficacy of the anti-CD38 monoclonal antibody daratumumab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM).
Ixazomib plus Lenalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (RRMM): Results of the Phase 3 Tourmaline-MM1 Study
First interim analysis results of the randomized, placebo-controlled phase 3 Tourmaline-MM1 study that evaluated the oral investigational proteasome inhibitor ixazomib in combination with lenalidomide and dexamethasone versus placebo plus lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM) were reported. Outcomes in patients with high-risk cytogenetics were also presented.
Researchers reported preliminary results of an ongoing, randomized, open-label phase 2 study that is evaluating the combination of the proteasome inhibitor carfilzomib plus the kinesin spindle protein inhibitor filanesib versus carfilzomib alone in patients with relapsed/refractory multiple myeloma.
Subgroup Analysis of the ENDEAVOR Study of Carfilzomib/Dexamethasone versus Bortezomib/Dexamethasone in Patients with Relapsed MM
Researchers presented a subgroup analysis of the impact of prior treatment (ie, after first relapse, ≥2 prior lines of therapy), and prior exposure to bortezomib or lenalidomide, on the efficacy and safety of carfilzomib plus dexamethasone versus bortezomib plus dexamethasone treatment in the randomized phase 3 ENDEAVOR study.
Subgroup Analysis Based on Cytogenetic Risk Status: Carfilzomib/Lenalidomide/Dexamethasone versus Lenalidomide/Dexamethasone (ASPIRE Study)
Avet-Loiseau and colleagues presented results of a preplanned subgroup analysis of the ASPIRE study that evaluated carfilzomib/lenalidomide/dexamethasone therapy versus standard lenalidomide/dexamethasone in patients with relapsed multiple myeloma (MM) based on baseline cytogenetic risk status.
Page 1 of 3
Results 1 - 10 of 25
Results 1 - 10 of 25